1, oral medications: similar to other dystonia, patients with oculofacial spasm can choose anticholinergic drugs, such as benzhexol; muscle relaxants, such as baclofen; benzodiazepines, such as clonazepam. However, this this drug has limited efficacy and is poorly tolerated by most patients due to side effects such as oral thousand and dizziness during dosing. 2, Botulinum toxin local injection: the application of botulinum toxin for blepharospasm is currently one of the preferred, fastest and most effective treatment methods in the world. The Chinese Expert Consensus on the Treatment of Dystonia (2020 version) states that a Level I evidence and three Level II evidence studies confirm that botulinum toxin can improve the spasticity of blepharospasm, improve ocular discomfort, and improve daily living ability. Adverse effects of botulinum toxin for blepharospasm are usually mild and include ptosis, blurred vision, and incomplete lid closure. Because of its well-documented safety and efficacy in treating blepharospasm, botulinum toxin is recommended as a first-line treatment for blepharospasm (Figure 1: a patient with blepharospasm; Figure 2: botulinum toxin injection into the orbicularis oculi point). 3. Cervical nerve node block: It is important to treat blepharospasm by reducing the motor neurological triggers of the disease, especially in some perceptual disorders, which can cause symptoms such as ocular surface irritation and photophobia. Cervical nerve node block therapy (chemical denervation of the orbital sympathetic nerve) has been reported to significantly reduce neurological irritation symptoms. 4. Simple peripheral facial nerve branch dissection: selective excision of the frontal and zygomatic branches of the facial nerve branches reduces contractures of the eyelid and brow muscles they innervate. Although it can reduce or relieve blepharospasm, it is prone to a series of complications of facial nerve palsy: brow ptosis, corneal exposure, and blepharospasm. This method can no longer be used clinically as a stand-alone treatment. 5, microscopic neurovascular decompression: for vascular variation and compression of the facial nerve, intracranial microvascular decompression with the seventh cranial nerve has been partially successful, with 88% of patients being cured and a recurrence rate of only 10%. According to Takashi Fukushima in Japan, microscopic neurovascular decompression was performed in 590 patients with severe blepharospasm using a small incision behind the ear, with an overall cure rate of 99.5%. 6. Myotomy: The purpose of myotomy is to remove the spastic periorbital and orbicularis oculi muscles using traditional surgical methods to reduce or eliminate the muscle contracture from outside the periorbital area, relieving functional blindness due to tightly closed lids and restoring vision.